andexanet alfa

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Home
Ligands
andexanet alfa

GtoPdb Ligand ID: 7576

andexanet alfa is an approved drug (FDA (2018), EMA (2019))

Compound class: Peptide

Comment: Andexanet alfa is a recombinant modified human Factor Xa (FXa) protein that acts as a mimetic of endogenous human factor Xa, and which was developed as a universal antidote to reverse thhe anticoagulant effects of direct or indirect FXa inhibitors. Information regarding the invention of andexanet alfa is available in patent WO2009042962 [2].

View more information in the IUPHAR Pharmacology Education Project: andexanet alfa

References
1. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB et al.. (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med, 19 (4): 446-51. [PMID:23455714]
2. Lu G, Phillips DR, Andre P, Sinha U. (2009) Antidotes for factor xa inhibitors and methods of using the same. Patent number: WO2009042962 A2. Assignee: Portola Pharm Inc and Inventors.. Priority date: 28/08/2007. Publication date: 02/04/2009.
3. Rogers KC, Finks SW. (2019) A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA). Am J Med, 132 (1): 38-41. [PMID:30053385]
4. Shaw JR, Siegal DM. (2018) Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature. Res Pract Thromb Haemost, 2 (2): 251-265. [PMID:30046727]

References

1. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB et al.. (2013)
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
Nat Med, 19 (4): 446-51. [PMID:23455714]

2. Lu G, Phillips DR, Andre P, Sinha U. (2009)
Antidotes for factor xa inhibitors and methods of using the same.
Patent number: WO2009042962 A2. Assignee: Portola Pharm Inc and Inventors.. Priority date: 28/08/2007. Publication date: 02/04/2009.

3. Rogers KC, Finks SW. (2019)
A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
Am J Med, 132 (1): 38-41. [PMID:30053385]

4. Shaw JR, Siegal DM. (2018)
Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature.
Res Pract Thromb Haemost, 2 (2): 251-265. [PMID:30046727]